Aclaris Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ACRS Nasdaq 2830 www.aclaristx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aclaris Therapeutics, Inc.

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Aug 10th, 2026 7:55 am
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) - Aug 6th, 2026 2:35 pm
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates - Aug 6th, 2026 6:20 am
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Aug 6th, 2026 4:59 am
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Jul 1st, 2026 6:23 am
3 Penny Stocks Under $5 Backed by Real Revenue Growth - Jun 20th, 2026 7:20 am
Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On - Jun 7th, 2026 11:59 am
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 - Jun 4th, 2026 1:02 pm
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - May 28th, 2026 6:30 am
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference - May 8th, 2026 6:30 am
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates - May 7th, 2026 6:50 am
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - May 7th, 2026 4:59 am
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth - May 4th, 2026 4:04 am
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus - Apr 28th, 2026 8:17 am
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor - Apr 28th, 2026 4:30 am
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 - Apr 27th, 2026 2:45 pm
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 - Mar 27th, 2026 8:10 am